719
Participants
Start Date
July 6, 2012
Primary Completion Date
March 10, 2017
Study Completion Date
March 10, 2017
Bevacizumab
Bevacizumab was administered as part of standard first-line treatment
Capecitabine/Oxaliplatin
Capecitabine/oxaliplatin were administered along with bevacizumab as part of standard first-line treatment
Fluorouracil/Folinic Acid/Oxaliplatin
Fluorouracil/folinic acid/oxaliplatin were administered along with bevacizumab as part of standard first-line treatment
Capecitabine
Capecitabine was administered along with bevacizumab as part of standard first-line treatment
Fluorouracil/Folinic Acid/Irinotecan
Fluorouracil/folinic acid/irinotecan were administered along with bevacizumab as part of standard first-line treatment
Fluorouracil +/- Folinic Acid
Fluorouracil +/- folinic acid were administered along with bevacizumab as part of standard first-line treatment
Royal United Hospital Bath; Diabetes and Lipid Research, Wolfson Centre, Bath
Wexham Park Hospital; Oncology, Berkshire
Queen Elizabeth Hospital, Birmingham
Birmingham Heartlands Hospital; Dept of Oncology, Birmingham
Bishop Auckland Hospital;Oncology Department, Bishop Auckland
University Hospital of North Staffordhire, Blackpool
Bradford Royal Infirmary; Dept of Medical Oncology C/O Ward15, Bradford
Bristol Haematology and Oncology Centre, Bristol
West Suffolk Hospital Nhs Trust; Gi Corridor, Bury St Edmunds
Kent & Canterbury Hospital, Canterbury
Cumberland Infirmary; Oncology Department, Carlisle
Broomfield Hospital; Oncology, Chelsmford
University Hospital North Tees, Cleveland
Castle Hill Hospital; Academic Oncology, Cottingham
Darlington Memorial Hospital, Darlington
Russells Hall Hospital; Dept of Hematology, Dudley
University Hospital of North Durham; Oncology, Durham
Harrogate Hospital, Harrogate
Northhwick Park Hospital;Oncology Department, Harrow
Ipswich Hospital; Oncology Pharmacy, Ipswich
Kidderminster Hospital; Oncology Dept, Kidderminster
Royal Free Hospital; Dept of Oncology, London
Guys Hosp./Med. Onc./3rd Fl. T; Clinical Trial Office, London
Queen Elizabeth Hospital, London
Macclesfield District General Hospital, Macclesfield
Maidstone & Tonbridge Wells Hospital; Kent Oncology Center, Maidstone
The James Cook University Hospital, Middlesbrough
Freeman Hospital, Newcastle upon Tyne
North Tyneside General Hospital, North Shields
Mount Vernon Cancer Centre, Northwood
Nottingham University Hospitals City Campus, Nottingham
Peterborough City Hospital, Edith Cavell Campus; Oncology Department, Peterborough
Derriford Hospital; Gastroenterology, Plymouth
Queen's Hospital, Romford
Scunthorpe General Hospital; Dept of Oncology, Scunthorpe
Stafford Hospital; Oncology Department, Stafford
The Royal Marsden Hospital, Sutton
Great Western Hospital, Swindon Cancer Research Unit; Osprey Unit Level 3, Swindon
Torbay Hospital; Oncology, Torquay
Royal Cornwall Hospital; Dept of Clinical Oncology, Truro
Walsall Manor Hospital, Walsall
Royal Hampshire County Hospital; Winchester & Andover Breast Unit, Winchester
The Royal Wolverhampton Hospitals NHS Trust, Wolverhampton
Hoffmann-La Roche
INDUSTRY